M Pharmaceutical is committed to developing and commercializing innovative drug treatments and biomedical technologies that improve the lives of people struggling with obesity, infertility and intimacy. The Company has the exclusive rights to the obesity drug C-103, a reformulation of Orlistat, in both prescription strength and over the counter formulations. Our company has also secured the exclusive rights for a women’s health product to treat infertility called ToConceive. In addition, M Pharmaceutical holds the rights to Trimeo Weight Loss Capsules, an obesity management technology deploying temporary controllable pseudobezoars, an innovative method for non-invasive dynamic gastric volume reduction for weight loss that has been recently tested in blind, placebo-controlled human studies. Commercial development of drug treatments and biomedical technologies will require successful coordination and execution of a wide variety of technology disciplines.
M Pharmaceutical is focused on providing drug treatments and biomedical technologies that improve the health and outcomes for people facing the medical issues of obesity & infertility, and intimacy issues.
M Pharmaceutical is committed to developing and commercializing its innovative drug treatments and biomedical technologies which offer the end user realistic solutions based on the principles of reduced invasiveness and enhanced effectiveness.
Drug Treatment Portfolio
Obesity, Weight Management Treatment
C-103 is a novel reformulation of orlistat, patented until 2030 in the U.S. Orlistat is FDA-approved for weight management and sold by Roche as Xenical® (prescription) and by GlaxoSmithKline as alli® (over-the-counter). Proven safe and effective in over 100 clinical trials, orlistat is the best-selling weight loss medication of all time with peak sales over $900 million in 2007. The C-103 reformulation addresses adverse events reported by over 90% of orlistat users. These adverse events have led to the decline in Orlistat sales to approximately $200 million in recent years.
C-103 is intended to maintain the efficacy of orlistat while minimizing its socially unacceptable adverse events. Unlike other weight loss drugs:
Orlistat is not an amphetamine
Orlistat does not affect the central nervous system
Orlistat is not systemically absorbed
Orlistat is the only FDA-approved OTC weight loss drug because of its safety
Orlistat is the only FDA-approved weight loss drug for adolescent patients (age 12-18)
ToConceive is an innovative new infertility treatment that offers hope and assistance to the millions of couples worldwide struggling to start a family. Our product is an easy to use topical gel that helps to balance the pH of the vagina and is clinically proven to increases a women’s natural production of transudate (sexual lubrication). This increase in natural transudate is required for successful “Sperm Capacitation” to occur. Without the process of Sperm Capacitation, the sperm would not have the ability to travel the required distance to the ovum or have the appropriate chemical makeup for successful conception to occur.
ToConceive is a women’s health treatment supported by a FDA 510K clearance and is protected by four USPTO patents. ToConceive’s proven ability to increase a woman’s natural production of transudate results in significantly higher success rates for couples trying to conceive, without the added expense, or stress, associated with assisted reproduction treatments.
Biomedical Technology Portfolio
M Pharmaceutical has exclusive rights to Trimeo Weight Loss Capsules, a biomedical technology to manage obesity and diabetes.
Obesity Management Treatment
Trimeo Weight Loss Capsules are drug free, individually controllable expandable implements that result in a dynamic gastric volume reduction, inducing a feeling of early satiety and reducing food intake. This third generation technology has 3 US and Canadian patents, 3 issued in the EU and 4 pending patents.
Management & Board of Directors
Gary A. Thompson, B.S., President & CEO M-Pharmaceutical U.S.A. Inc.
30 years plus of sales and management experience in Fortune 500 health care organizations and start up pharmaceutical companies.
He has served as Vice President of sales for Cigna Healthcare managing billions of assets over his career.
Management and leadership roles with start up ventures including ToConceive LLC., (510K FDA Clearance ) in women's health and wellness, and in the obesity space as President of M-Pharma's newly acquired Chelatexx, LLC., C-103 reformulated orlistat.
Brian Keane, BSc, Interim President and CEO
17 years in capital markets experience
Experience with investment funds
Experience working in several investment banks
Dr. Christopher Andrews, M.D., MSc, FRCPC, Director
Gastroenterologist, faculty member of the Department of Medicine at the University of Calgary and graduate of the Mayo Clinic in Rochester, MN
Specialist in stomach disorders and physiology, with advanced training in gastrointestinal motility and function
Masters Degree in Clinical Health Research from the Mayo Clinic
D. Richard Skeith, BA/JD, Director
BA (Hons) in Economics, University of Alberta; JD Faculty of Law, University of Alberta
Practicing Lawyer with specialized focus on publicly traded companies
Extensive experience as an Officer or Director of multiple public companies in sectors including pharmaceuticals, mining, oil and gas and real estate